Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026
Company Deals

China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio

Fineline Cube Apr 27, 2026
Company Deals

Johnson & Johnson Acquires Atraverse Medical to Expand Cardiac Ablation Portfolio with Next-Gen Left-Heart Access Technology

Fineline Cube Apr 27, 2026
Company Deals

Star Sports Medicine Raises HKD 830 Million in Hong Kong IPO as China’s Leading Domestic Sports Medicine Provider

Fineline Cube Apr 24, 2026
Company Deals

Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China’s Long-Acting Botulinum Toxin Market

Fineline Cube Apr 24, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Sanofi Secures CHMP Positive Opinion for Cenrifki (Tolebrutinib) in Non-Relapsing SPMS Despite FDA Complete Response Letter Setback

Fineline Cube Apr 27, 2026
Company Drug

Novartis Withdraws Pluvicto Pre-Chemotherapy mCRPC Application in EU Following CHMP Objections on PSMAfore Control Arm Design

Fineline Cube Apr 27, 2026
Company Deals

Merck Sharp & Dohme Partners with Sinopharm for Molnupiravir in China

Fineline Cube Sep 28, 2022

US-based Merck Sharp & Dohme (MSD, NYSE: MRK) has entered into a cooperation framework agreement...

Company Drug

NMPA Releases 59th Batch of Reference Drugs for Generic Quality Evaluation

Fineline Cube Sep 28, 2022

The National Medical Products Administration (NMPA) has released the 59th batch of reference drugs for...

Company

SciClone Pharmaceuticals Reports 10.8% Revenue Growth in 2022 Interim Results

Fineline Cube Sep 28, 2022

SciClone Pharmaceuticals Inc., formerly a US-based and Nasdaq-listed company that became China-based after going private...

Company Drug

Harbour BioMed Doses First Subject in Phase I Study for HBM9378 in China

Fineline Cube Sep 28, 2022

China-based Harbour BioMed (HKG: 2142) has announced the completion of the first subject dosing in...

Company Medical Device

MicroPort CardioFlow’s Alwide Plus Balloon Catheter Approved in Colombia

Fineline Cube Sep 28, 2022

MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), a spin-off of China-based MicroPort Scientific Corp (HKG:...

Company Deals

Zai Lab Licenses Seagen’s Tivdak for Greater China Development and Commercialization

Fineline Cube Sep 28, 2022

Chinese firm Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) has formed a collaboration with US-based...

Company Drug

Telix Pharmaceuticals Gains IND Approval for TLX250-CDx in China

Fineline Cube Sep 28, 2022

Australia-based Telix Pharmaceuticals Ltd (ASX: TLX) has announced that it has received Investigational New Drug...

Company Drug

Fosun Pharma Launches 20ml SPSB Liquid Product in US Market

Fineline Cube Sep 28, 2022

Shanghai Fosun Pharma (Group) Co., Ltd (SHA: 600196, HKG: 2196) has reported the market launch...

Company

Merck’s Gabor Outlines AI and Biomedicine Strategy in China

Fineline Cube Sep 28, 2022

Allan Gabor, president of Merck KGaA China and executive vice president of Merck Electronics, shared...

Company Deals

Luye Pharma Grants ICI Pakistan Distribution Rights for Schizophrenia Drug Seroquel

Fineline Cube Sep 28, 2022

China-based Luye Pharma Group has reportedly handed over the distribution and marketing rights for its...

Company Medical Device

Sino Medical Sciences Gains Approval for Drug-Eluting Stent System

Fineline Cube Sep 27, 2022

China-based Sino Medical Sciences Technology Inc. (SHA: 688108) has announced that it has received market...

Company Drug

Tris Pharma and Pediatrix Therapeutics’ ADHD Drug Gains Priority Review in China

Fineline Cube Sep 27, 2022

The Center for Drug Evaluation (CDE) has indicated that the methylphenidate hydrochloride oral sustained-release dry...

Company Drug

Angel Pharmaceuticals Gains CDE Approval for Mupadolimab Phase I/Ib Study

Fineline Cube Sep 27, 2022

China-based Angel Pharmaceuticals Ltd has announced that it has received approval from the Center for...

Company

YiChang HEC Reports Strong Recovery in 2022 Interim Results

Fineline Cube Sep 27, 2022

China-based YiChang HEC ChangJiang Pharmaceutical Co., Ltd (HKG: 1558) has released its 2022 interim report,...

Company

Sino Biopharmaceutical Reports Mixed Results in 2022 Interim Report

Fineline Cube Sep 27, 2022

China-based Sino Biopharmaceutical Ltd (HKG: 1177) has released its 2022 interim report, recording revenues of...

Company Deals Drug

Gluetacs Therapeutics Files IND for Molecular Glue Degrading Agent in China

Fineline Cube Sep 27, 2022

Gluetacs Therapeutics has reported filing an Investigational New Drug (IND) application for its first molecular...

Company

Global Cord Blood Corporation Appoints Liquidators Amid Shareholder Dispute

Fineline Cube Sep 27, 2022

Global Cord Blood Corporation (OTCMKTS: CORBF) has announced that the Grand Court of the Cayman...

Company Deals

Hansoh Pharmaceutical Licenses KiOmedine One for Osteoarthritis Treatment

Fineline Cube Sep 27, 2022

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced a licensing agreement with Belgium’s...

Company Deals

Ubrigene Raises Hundreds of Millions in Series C Financing Round

Fineline Cube Sep 27, 2022

Yiming (Beijing) Cell Biotechnology Co., Ltd, also known as Ubrigene, a gene and cell therapy...

Company Medical Device

China’s First Proton Therapy System Approved by NMPA

Fineline Cube Sep 27, 2022

The National Medical Products Administration (NMPA) has approved the proton therapy system developed by Shanghai...

Posts pagination

1 … 611 612 613 … 657

Recent updates

  • Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets
  • Boehringer Ingelheim Launches Pulmonary Fibrosis Care Initiative in China with CNR News, Tencent Medipedia, and Patient Groups to Combat Underdiagnosed Fatal Lung Disease
  • Sanofi Secures CHMP Positive Opinion for Cenrifki (Tolebrutinib) in Non-Relapsing SPMS Despite FDA Complete Response Letter Setback
  • China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio
  • Novartis Withdraws Pluvicto Pre-Chemotherapy mCRPC Application in EU Following CHMP Objections on PSMAfore Control Arm Design
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Company

Boehringer Ingelheim Launches Pulmonary Fibrosis Care Initiative in China with CNR News, Tencent Medipedia, and Patient Groups to Combat Underdiagnosed Fatal Lung Disease

Company Drug

Sanofi Secures CHMP Positive Opinion for Cenrifki (Tolebrutinib) in Non-Relapsing SPMS Despite FDA Complete Response Letter Setback

Company Deals

China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.